{"id":52920,"date":"2026-01-05T22:51:48","date_gmt":"2026-01-05T14:51:48","guid":{"rendered":"https:\/\/flcube.com\/?p=52920"},"modified":"2026-01-05T22:51:49","modified_gmt":"2026-01-05T14:51:49","slug":"kelun-biotechs-sac-tmt-wins-breakthrough-therapy-designation-for-first-line-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52920","title":{"rendered":"Kelun-Biotech&#8217;s sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC"},"content":{"rendered":"\n<p><strong>Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6990:HKG\">HKG: 6990<\/a>) announced that <strong>sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870)<\/strong>, its <strong>TROP2\u2011directed ADC<\/strong>, in combination with <strong>MSD\u2019s pembrolizumab (KEYTRUDA)<\/strong>, has been granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> by China\u2019s <strong>Center for Drug Evaluation (CDE)<\/strong> for <strong>first\u2011line treatment<\/strong> of <strong>locally advanced or metastatic NSCLC<\/strong> (PD\u2011L1 TPS \u22651%, EGFR\u2011negative, ALK\u2011negative).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-breakthrough-designation-amp-clinical-basis\">Breakthrough Designation &amp; Clinical Basis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Sichuan Kelun\u2011Biotech (6990.HK)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>MSD (Merck) for pembrolizumab combination<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (CDE\/NMPA)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line NSCLC (PD\u2011L1 \u22651%, EGFR\u2011negative, ALK\u2011negative)<\/td><\/tr><tr><td><strong>Trial<\/strong><\/td><td>Phase\u202f3 OptiTROPLung05<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression\u2011free survival (PFS) \u2013 <strong>statistically significant improvement<\/strong><\/td><\/tr><tr><td><strong>Secondary Endpoint<\/strong><\/td><td>Overall survival (OS) \u2013 <strong>positive trend observed<\/strong><\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First Phase\u202f3 immunotherapy + ADC combo<\/strong> to meet primary endpoint in 1L NSCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-3-optitroplung05-trial\">Phase\u202f3 OptiTROPLung05 Trial<\/h2>\n\n\n\n<p><strong>Design<\/strong>: Multicenter, randomized study evaluating sac\u2011TMT + pembrolizumab vs. pembrolizumab alone in <strong>PD\u2011L1\u2011positive NSCLC<\/strong>.<\/p>\n\n\n\n<p><strong>Results<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PFS<\/strong>: Statistically significant and clinically meaningful improvement<\/li>\n\n\n\n<li><strong>OS<\/strong>: Positive trend favoring combination arm<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Manageable toxicity profile consistent with individual agents<\/li>\n<\/ul>\n\n\n\n<p>This marks the <strong>first time<\/strong> a TROP2 ADC + immunotherapy combination has demonstrated superiority in <strong>first\u2011line NSCLC<\/strong>, positioning sac\u2011TMT as a potential <strong>new standard of care<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-commercial-status-in-china\">Regulatory &amp; Commercial Status in China<\/h2>\n\n\n\n<p><strong>Already Approved\/Marketed<\/strong>:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>EGFR\u2011mutant NSCLC<\/strong> (post\u2011EGFR\u2011TKI + platinum chemotherapy) \u2013 <em>NRDL included<\/em><\/li>\n\n\n\n<li><strong>Unresectable locally advanced\/metastatic TNBC<\/strong> (\u22652 prior systemic therapies) \u2013 <em>NRDL included<\/em><\/li>\n\n\n\n<li><strong>EGFR\u2011mutant NSCLC<\/strong> (post\u2011EGFR\u2011TKI) \u2013 <em>Market approved<\/em><\/li>\n<\/ol>\n\n\n\n<p><strong>Global Licensing<\/strong>: In <strong>May\u202f2022<\/strong>, Kelun\u2011Biotech licensed <strong>exclusive ex\u2011Greater China rights<\/strong> to MSD for <strong>sac\u2011TMT<\/strong> development and commercialization.<\/p>\n\n\n\n<p><strong>Manufacturing<\/strong>: Kelun retains <strong>Greater China manufacturing rights<\/strong> with <strong>capacity for 200+ kg\/year<\/strong> at its Chengdu facility.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-first-line-nsclc-in-china\">Market Opportunity: First\u2011Line NSCLC in China<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NSCLC Incidence<\/strong>: <strong>~800,000<\/strong> new cases annually in China<\/li>\n\n\n\n<li><strong>PD\u2011L1\u2011Positive (\u22651%)<\/strong>: <strong>~55\u201160%<\/strong> of patients \u2192 <strong>~440,000<\/strong> eligible<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: <strong>First\u2011line<\/strong> setting represents <strong>largest opportunity<\/strong> (vs. later lines)<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China NSCLC Market<\/strong>: <strong>\u00a545\u202fbillion<\/strong> (2025), growing at <strong>12% CAGR<\/strong><\/li>\n\n\n\n<li><strong>ADC + IO Segment<\/strong>: <strong>\u00a58\u201110\u202fbillion<\/strong> potential by 2030<\/li>\n\n\n\n<li><strong>Sac\u2011TMT Projected Peak Sales<\/strong>: <strong>\u00a56\u20118\u202fbillion<\/strong> (US$840M\u20111.1B) in NSCLC alone<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Landscape<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TROP2 ADCs<\/strong>: <strong>Datopotamab deruxtecan<\/strong> (AZ\/Daiichi) \u2013 Phase\u202f3 ongoing<\/li>\n\n\n\n<li><strong>Sac\u2011TMT Advantage<\/strong>: <strong>First to demonstrate Phase\u202f3 success<\/strong> in 1L NSCLC; <strong>9\u201112 month head start<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications-amp-deal-economics\">Financial Implications &amp; Deal Economics<\/h2>\n\n\n\n<p><strong>MSD Partnership<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront<\/strong>: <strong>USD\u202f100\u202fmillion<\/strong> (received 2022)<\/li>\n\n\n\n<li><strong>Milestones<\/strong>: Up to <strong>USD\u202f1.5\u202fbillion<\/strong> (development + commercial)<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: <strong>Mid\u2011teens to high\u2011teens<\/strong> on ex\u2011China sales<\/li>\n<\/ul>\n\n\n\n<p><strong>China Economics<\/strong>: Kelun retains <strong>100% of Greater China revenue<\/strong>, projected <strong>\u00a520\u202fbillion+<\/strong> peak across all indications.<\/p>\n\n\n\n<p><strong>Stock Impact<\/strong>: BTD designation <strong>derisks regulatory pathway<\/strong> and could trigger <strong>MSD milestone payments<\/strong> upon NDA filing.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding sac\u2011TMT\u2019s clinical development, regulatory approvals, market penetration, and revenue projections. Actual results may differ materially due to competitive dynamics, regulatory review timelines, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870), its TROP2\u2011directed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52922,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,34,29,971,1832,2675,176,18],"class_list":["post-52920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-breakthrough-therapy","tag-combination-therapy","tag-hkg-6990","tag-kelun-biotech-biopharmaceutical","tag-merck-sharp-dohme","tag-msd","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelun-Biotech&#039;s sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870), its TROP2\u2011directed ADC, in combination with MSD\u2019s pembrolizumab (KEYTRUDA), has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC (PD\u2011L1 TPS \u22651%, EGFR\u2011negative, ALK\u2011negative).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52920\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelun-Biotech&#039;s sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC\" \/>\n<meta property=\"og:description\" content=\"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870), its TROP2\u2011directed ADC, in combination with MSD\u2019s pembrolizumab (KEYTRUDA), has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC (PD\u2011L1 TPS \u22651%, EGFR\u2011negative, ALK\u2011negative).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52920\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T14:51:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T14:51:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0507.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelun-Biotech&#8217;s sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC\",\"datePublished\":\"2026-01-05T14:51:48+00:00\",\"dateModified\":\"2026-01-05T14:51:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0507.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Breakthrough therapy\",\"Combination therapy\",\"HKG: 6990\",\"Kelun-Biotech Biopharmaceutical\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52920#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52920\",\"name\":\"Kelun-Biotech's sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0507.webp\",\"datePublished\":\"2026-01-05T14:51:48+00:00\",\"dateModified\":\"2026-01-05T14:51:49+00:00\",\"description\":\"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac\u2011TMT, SKB264\\\/MK\u20112870), its TROP2\u2011directed ADC, in combination with MSD\u2019s pembrolizumab (KEYTRUDA), has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC (PD\u2011L1 TPS \u22651%, EGFR\u2011negative, ALK\u2011negative).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52920\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0507.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0507.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kelun-Biotech's sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52920#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelun-Biotech&#8217;s sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelun-Biotech's sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870), its TROP2\u2011directed ADC, in combination with MSD\u2019s pembrolizumab (KEYTRUDA), has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC (PD\u2011L1 TPS \u22651%, EGFR\u2011negative, ALK\u2011negative).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52920","og_locale":"en_US","og_type":"article","og_title":"Kelun-Biotech's sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC","og_description":"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870), its TROP2\u2011directed ADC, in combination with MSD\u2019s pembrolizumab (KEYTRUDA), has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC (PD\u2011L1 TPS \u22651%, EGFR\u2011negative, ALK\u2011negative).","og_url":"https:\/\/flcube.com\/?p=52920","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-05T14:51:48+00:00","article_modified_time":"2026-01-05T14:51:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0507.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52920#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52920"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelun-Biotech&#8217;s sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC","datePublished":"2026-01-05T14:51:48+00:00","dateModified":"2026-01-05T14:51:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52920"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0507.webp","keywords":["ADC \/ XDC","Breakthrough therapy","Combination therapy","HKG: 6990","Kelun-Biotech Biopharmaceutical","Merck Sharp &amp; Dohme","MSD","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52920#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52920","url":"https:\/\/flcube.com\/?p=52920","name":"Kelun-Biotech's sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52920#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0507.webp","datePublished":"2026-01-05T14:51:48+00:00","dateModified":"2026-01-05T14:51:49+00:00","description":"Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac\u2011TMT, SKB264\/MK\u20112870), its TROP2\u2011directed ADC, in combination with MSD\u2019s pembrolizumab (KEYTRUDA), has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first\u2011line treatment of locally advanced or metastatic NSCLC (PD\u2011L1 TPS \u22651%, EGFR\u2011negative, ALK\u2011negative).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52920#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52920"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52920#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0507.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0507.webp","width":1080,"height":608,"caption":"Kelun-Biotech's sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52920#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelun-Biotech&#8217;s sac-TMT Wins Breakthrough Therapy Designation for First\u2011Line NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0507.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52920"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52920\/revisions"}],"predecessor-version":[{"id":52923,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52920\/revisions\/52923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52922"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}